JP2009518447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518447A5 JP2009518447A5 JP2008544662A JP2008544662A JP2009518447A5 JP 2009518447 A5 JP2009518447 A5 JP 2009518447A5 JP 2008544662 A JP2008544662 A JP 2008544662A JP 2008544662 A JP2008544662 A JP 2008544662A JP 2009518447 A5 JP2009518447 A5 JP 2009518447A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- antibody
- proteasome inhibitor
- fragment
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74915205P | 2005-12-09 | 2005-12-09 | |
| PCT/US2006/061786 WO2007067976A2 (en) | 2005-12-09 | 2006-12-08 | Method of using il6 antagonists with proteasome inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518447A JP2009518447A (ja) | 2009-05-07 |
| JP2009518447A5 true JP2009518447A5 (enExample) | 2009-11-12 |
Family
ID=38123650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544662A Pending JP2009518447A (ja) | 2005-12-09 | 2006-12-08 | プロテアソームインヒビターと併せたｉｌ６アンタゴニストの使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090022726A1 (enExample) |
| EP (1) | EP1954310A4 (enExample) |
| JP (1) | JP2009518447A (enExample) |
| KR (1) | KR20080072761A (enExample) |
| CN (1) | CN101325969A (enExample) |
| AR (1) | AR057227A1 (enExample) |
| AU (1) | AU2006321610A1 (enExample) |
| BR (1) | BRPI0619498A2 (enExample) |
| CA (1) | CA2632732A1 (enExample) |
| EA (1) | EA014675B1 (enExample) |
| IL (1) | IL191694A0 (enExample) |
| NO (1) | NO20082907L (enExample) |
| TW (1) | TW200803895A (enExample) |
| WO (1) | WO2007067976A2 (enExample) |
| ZA (1) | ZA200805956B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509879A (pt) | 2004-04-15 | 2007-10-16 | Proteolix Inc | compostos para inibição enzimática |
| US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| US8088741B2 (en) | 2004-05-10 | 2012-01-03 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
| NZ595196A (en) | 2005-11-09 | 2013-03-28 | Proteolix Inc | Peptide-based compounds for enzyme inhibition |
| AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| JP5033643B2 (ja) * | 2006-01-27 | 2012-09-26 | 学校法人慶應義塾 | 脈絡膜血管新生を伴う疾患の治療剤 |
| WO2007116962A1 (ja) * | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| BRPI0713309A2 (pt) | 2006-06-19 | 2012-04-17 | Proteolix Inc | compostos para inibição de enzimas |
| TWI438208B (zh) | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
| JP5424330B2 (ja) * | 2007-07-26 | 2014-02-26 | 国立大学法人大阪大学 | インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
| ES2684340T3 (es) | 2007-10-04 | 2018-10-02 | Onyx Therapeutics, Inc. | Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos |
| CA2728243C (en) | 2008-06-05 | 2020-03-10 | National Cancer Center | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| EA201170527A1 (ru) * | 2008-10-01 | 2011-10-31 | Др. Редди'С Лабораторис Лтд. | Фармацевтические композиции, включающие соединения бороновой кислоты |
| EA035100B1 (ru) | 2008-10-21 | 2020-04-28 | Оникс Терапьютикс, Инк. | Комбинированная терапия с применением пептид эпоксикетонов |
| CN102271683B (zh) * | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| EP2464666B1 (en) | 2009-07-15 | 2018-03-21 | Eva Kovacs-Benke | Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases |
| MY161541A (en) * | 2009-07-31 | 2017-04-28 | Shin Maeda | Cancer metastasis inhibitor |
| US7947653B1 (en) | 2009-10-09 | 2011-05-24 | Cold Spring Harbor Laboratory | Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers |
| US8323883B1 (en) | 2009-10-09 | 2012-12-04 | Cold Spring Harbor Laboratory | Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
| ES2932398T3 (es) | 2010-05-28 | 2023-01-18 | Chugai Pharmaceutical Co Ltd | Potenciador de la respuesta de las células T antitumorales |
| WO2012122359A2 (en) * | 2011-03-10 | 2012-09-13 | Albert Einstein College Of Medicine Of Yeshiva University | Target directed to adipocytes, methods and assays for treatment of obesity |
| WO2013175276A1 (en) * | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| KR101643041B1 (ko) * | 2014-04-25 | 2016-07-28 | 아주대학교산학협력단 | 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물 |
| CN104922659B (zh) * | 2015-07-03 | 2018-04-20 | 刘永庆 | 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用 |
| WO2017138008A2 (en) * | 2016-02-14 | 2017-08-17 | Yeda Research And Development Co. Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| US20200246488A1 (en) * | 2017-07-17 | 2020-08-06 | The Broad Institute, Inc. | Compositions and methods for treating inflammatory bowel diseases |
| KR102771895B1 (ko) | 2017-10-20 | 2025-02-21 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
| US20200165608A1 (en) * | 2018-11-23 | 2020-05-28 | Florida State University Research Foundation, Inc. | Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210075A (en) * | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
| US5340736A (en) * | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| TW458985B (en) * | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| US5693617A (en) * | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| DE69920940T2 (de) * | 1998-10-20 | 2005-11-17 | Millennium Pharmaceuticals, Inc., Cambridge | Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte |
| NZ533223A (en) * | 2001-11-14 | 2007-04-27 | Centocor Inc | Anti-il-6 antibodies, compositions, methods and uses |
| EP1594897A4 (en) * | 2003-02-04 | 2006-11-08 | Centocor Inc | USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS |
| PE20061324A1 (es) * | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
-
2006
- 2006-12-07 AR ARP060105416A patent/AR057227A1/es not_active Application Discontinuation
- 2006-12-08 KR KR1020087016043A patent/KR20080072761A/ko not_active Withdrawn
- 2006-12-08 JP JP2008544662A patent/JP2009518447A/ja active Pending
- 2006-12-08 CA CA002632732A patent/CA2632732A1/en not_active Abandoned
- 2006-12-08 EP EP06840161A patent/EP1954310A4/en not_active Withdrawn
- 2006-12-08 CN CNA2006800459213A patent/CN101325969A/zh active Pending
- 2006-12-08 US US11/608,342 patent/US20090022726A1/en not_active Abandoned
- 2006-12-08 WO PCT/US2006/061786 patent/WO2007067976A2/en not_active Ceased
- 2006-12-08 EA EA200870029A patent/EA014675B1/ru not_active IP Right Cessation
- 2006-12-08 BR BRPI0619498-2A patent/BRPI0619498A2/pt not_active IP Right Cessation
- 2006-12-08 TW TW095145881A patent/TW200803895A/zh unknown
- 2006-12-08 AU AU2006321610A patent/AU2006321610A1/en not_active Abandoned
-
2008
- 2008-05-25 IL IL191694A patent/IL191694A0/en unknown
- 2008-06-27 NO NO20082907A patent/NO20082907L/no not_active Application Discontinuation
- 2008-07-08 ZA ZA200805956A patent/ZA200805956B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518447A5 (enExample) | ||
| Koganemaru et al. | U3-1402, a novel HER3-targeting antibody–drug conjugate, for the treatment of colorectal cancer | |
| JP2009518441A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| CN104039320B (zh) | 血液恶性肿瘤用抗-cxcr4抗体的治疗 | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| JP2007513073A5 (enExample) | ||
| JP2014502957A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2008530142A5 (enExample) | ||
| JP2009501800A5 (enExample) | ||
| JP2003501401A5 (enExample) | ||
| HRP20180945T1 (hr) | Konjugati protutijelo-pirolobenzodiazepin | |
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| JP2010515709A5 (enExample) | ||
| JP2007051159A5 (enExample) | ||
| RU2723937C2 (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2010500371A5 (enExample) | ||
| JP2020505433A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2008507529A5 (enExample) | ||
| JP2009526010A5 (enExample) | ||
| JP2013542179A5 (enExample) | ||
| JP2023129433A5 (enExample) | ||
| US20220003772A1 (en) | Methods of treating cancer |